A prospective, randomized, open-label study to compare the different dosage forms of omega 3 fatty acids as an adjuvant in the bipolar depression
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20252582Keywords:
CGI, Docosahexaenoic acid, Eicosapentaenoic acid, HAM-D, MADRSsAbstract
Background: Bipolar affective disorder is a chronic disorder in which bipolar depression (BD) has poor prognosis than mania. There is a lack of universal pharmacotherapy for BD, with standard drug therapy having multiple long term adverse effects. Omega-3 fatty acids (O3FAs) act on key BD pathology and found to have reduction on symptom severity in BD. Thus, this study aims to compare efficacy and safety of 2 different doses, 1.2 g/day and 2.4 g/day of O3FAs with control group in BD patients.
Methods: This is an interventional, randomized, open-label, prospective and parallel study of 12 weeks with patients (n=90) randomly divided into three groups. This study compared the control group (Group A, n=30) on standard drugs only, with 1.2 g/day OD of O3FAs (Group B, n=30) and 2.4 g/day BD of O3FAs (Group C, n=30). Evaluation of efficacy was done on basis of Hamilton Depression Rating Score (HAM-D), Montgomery-Asberg Depression Rating Scale (MADRS), Clinical Global Impression (CGI) scales every 15 days for 3 months. Adverse effects were reported every 15 days for 3 months.
Results: After 3 months of treatment, Group C had statistically significant improvement in HAM-D (p<0.01), MADRS (p<0.01) and CGI (p<0.01) scores as compared to group A and B. Group A (37) had of adverse effects than Group B (21) and C (17) at 3 months.
Conclusions: Group C seems to had better efficacy and safety as compared to Group B and baseline drugs alone. Further extensive research with large sample size and studies with longer duration are required to validate the role of O3FAs in BD.
Metrics
References
Müller-Oerlinghausen B, Berghöfer A, Bauer M. Bipolar disorder. Lancet. 2002;359(9302):241-7. DOI: https://doi.org/10.1016/S0140-6736(02)07450-0
Stanfill MH, Hsieh KL, Beal K, Fenton SH. Preparing for ICD-10-CM/PCS implementation: impact on productivity and quality. Perspectives in health information management. 2014.
Sadock BJ, Sadock VA, Ruiz P. Kaplan, Sadock’s synopsis of psychiatry: behavioral sciences-clinical psychiatry. 11th edition. Philadelphia, USA: Wolters Kluwer. 2015:347–67.
Sagar R, Dandona R, Gururaj G, Dhaliwal RS, Singh A, Ferrai A, et al. The burden of mental disorders across the states of India: the global burden of Disease Study 1990-2017. Lancet Psych. 2020;7(2):148–61 DOI: https://doi.org/10.1016/S2215-0366(19)30475-4
Hamilton M. Development of a Rating Scale for Primary Depressive Illness. J Soc Clin Psychol. 1967;6(4):278–96 DOI: https://doi.org/10.1111/j.2044-8260.1967.tb00530.x
Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W. Modification of the Clinical Global Impressions (CGI) scale for use in bipolar illness (BP)-the CGI-BP. Psych Res. 1997;73(3):159–71 DOI: https://doi.org/10.1016/S0165-1781(97)00123-6
Diagnostic and statistical manual of mental disorders: DSM-5TM, 5th ed. Arlington, VA, US: American Psychiatric Publishing, Inc. 2013:947
Shah N, Grover S, Rao Gp. Clinical practice guidelines for management of bipolar disorder. Indian J Psych. 2017;59(5):51. DOI: https://doi.org/10.4103/0019-5545.196974
Butler M, Urosevic S, Desai P, Sponheim SR, Popp J, Nelson VA, Thao V, Sunderlin B. Treatment for bipolar disorder in adults: a systematic review. 2018. DOI: https://doi.org/10.23970/AHRQEPCCER208
National Institute for Health and Care Excellence (Great Britain). Bipolar disorder: assessment and management. NICE, National Institute for Health and Care Excellence. 2019.
Solmi M, Murru A, Pacchiarotti I, Undurraga J, Veronese N, Fornaro M, et al. Safety, tolerability and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Ther Clin Risk Manag. 2017;13:757–77. DOI: https://doi.org/10.2147/TCRM.S117321
Lemaitre RN, Tanaka T, Tang W, Manichaikul A, Foy M, Kabagambe EK, et al. Genetic Loci Associated with Plasma Phospholipid n-3 Fatty Acids: A Meta-Analysis of Genome-Wide Association Studies from the CHARGE Consortium. PLoS Genet. 2011;7(7):1002193. DOI: https://doi.org/10.1371/journal.pgen.1002193
Guan W, Steffen BT, Lemaitre RN, Wu JHY, Tanaka T, Manichaikul A, et al. Genome-Wide Association Study of Plasma N6 Polyunsaturated Fatty Acids within the CHARGE Consortium. Circ Cardiovasc Genet. 2014;7(3):321–31. DOI: https://doi.org/10.1161/CIRCGENETICS.113.000208
Paduchová Z, Katrenčíková B, Vaváková M, Laubertová L, Nagyová Z, Garaiova I, et al. The Effect of Omega-3 Fatty Acids on Thromboxane, Brain- Derived Neurotrophic Factor, Homocysteine and Vitamin D in Depressive Children and Adolescents: Randomized Controlled Trial. Nutr. 2021;13(4):1095. DOI: https://doi.org/10.3390/nu13041095
Chiu CC, Huang SY, Su KP, Lu ML, Huang MC, Chen CC, et al. Polyunsaturated fatty acid deficit in patients with bipolar mania. European Neuropsychopharmacol. 2003;13(2):99–103. DOI: https://doi.org/10.1016/S0924-977X(02)00130-X
McNamara RK, Welge JA. Meta-analysis of erythrocyte polyunsaturated fatty acid biostatus in bipolar disorder. Bipolar Disord. 2016;18(3):300–6. DOI: https://doi.org/10.1111/bdi.12386
Robert, Hirschfeld, Charles L, Michael J, Keck P, Trisha Suppes, et al. APA- Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry. 2002;159(4):1–50.
Fountoulakis KN, Yatham LN, Grunze H, Vieta E, Young AH, Blier P, et al. The CINP Guidelines on the Definition and Evidence-Based Interventions for Treatment-Resistant Bipolar Disorder. Int J Neuropsychopharmacol. 2020;23(4):230–56. DOI: https://doi.org/10.1093/ijnp/pyz064
Malhi GS, Bell E, Bassett D, Boyce P, Bryant R, Hazell P, et al. The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Australian & New Zealand J Psych. 2021;55(1):7-117. DOI: https://doi.org/10.1177/0004867420979353
Indian Council of Medical Research. Expert Group. Nutrient requirements and recommended dietary allowances for Indians: a report of the Expert Group of the Indian Council of Medical Research. 2010.
Dwarkanath P, Muthayya S, Thomas T, Vaz M, Parikh P, Mehra R, et al. Polyunsaturated fatty acid consumption and concentration among South Indian women during pregnancy. Asia Pac J Clin Nutr. 2009;18(3):389-94
Arnold LE, Young AS, Belury MA, Cole RM, Gracious B, Seidenfeld AM, et al. Omega-3 Fatty Acid Plasma Levels Before and After Supplementation: Correlations with Mood and Clinical Outcomes in the Omega-3 and Therapy Studies. J Child Adolesc Psychopharmacol. 2017;27(3):223–33. DOI: https://doi.org/10.1089/cap.2016.0123
Clayton EH, Hanstock TL, Hirneth SJ, Kable CJ, Garg ML, Hazell PL. Reduced mania and depression in juvenile bipolar disorder associated with long-chain ω-3 polyunsaturated fatty acid supplementation. Eur J Clin Nutr. 2009;63(8):1037-40. DOI: https://doi.org/10.1038/ejcn.2008.81
Frangou S, Lewis M, McCrone P. Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: Randomised double-blind placebo-controlled study. Br J Psychiatry. 2006;188(1):46–50. DOI: https://doi.org/10.1192/bjp.188.1.46
Stoll AL, Severus WE, Freeman MP, Rueter S, Zboyan HA, Diamond E, Cress KK, Marangell LB. Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Arch Gen Psych. 1999;56(5):407-12. DOI: https://doi.org/10.1001/archpsyc.56.5.407
Murphy BL, Stoll AL, Harris PQ, Ravichandran C, Babb SM, Carlezon WAJ, et al. Omega-3 Fatty Acid Treatment, With or Without Cytidine, Fails to Show Therapeutic Properties in Bipolar Disorder: A Double-Blind, Randomized Add-on Clinical Trial. J Clin Psychopharmacol. 2012;32(5):699–703. DOI: https://doi.org/10.1097/JCP.0b013e318266854c
McPhilemy G, Byrne F, Waldron M, Hibbeln JR, Davis J, McDonald C, et al. A 52-week prophylactic randomised control trial of omega-3 polyunsaturated fatty acids in bipolar disorder. Bipolar Disord. 2021;23(7):697–706. DOI: https://doi.org/10.1111/bdi.13037
Dell’Osso B, Cafaro R, Ketter TA. Has Bipolar Disorder become a predominantly female gender related condition. Analysis of recently published large sample studies. Int J Bipolar Disord. 2021;9(1):3. DOI: https://doi.org/10.1186/s40345-020-00207-z
Wilde A, Chan HN, Rahman B, Meiser B, Mitchell PB, Schofield PR, et al. A meta-analysis of the risk of major affective disorder in relatives of individuals affected by major depressive disorder or bipolar disorder. J Affect Disord. 2014;158:37–47. DOI: https://doi.org/10.1016/j.jad.2014.01.014
Downloads
Published
How to Cite
Issue
Section
